From a molecular therapeutics standpoint, Relafen 750 ( Naproxen Acid) presents a fascinating case study in therapeutic action. Its mechanism of effect primarily involves the blockade of cyclooxygenase (COX ) enzymes, particularly the COX-2 isoform, leading to a diminution in the synthesis of PGE2 . This focused inhibition accounts for its pain-rel